Humanized CAR T cells targeting p95HER2
Roman, M.; Rius Ruiz, I.; Grinyo-Escuer, A.; Duro-Sanchez, S.; Escorihuela, M.; Moessner, E.; Klein, C.; Arribas, J.
Show abstract
Redirection of T lymphocytes against tumor-associated or tumor-specific antigens, via bispecifc T cells engagers (BiTEs) or chimeric antigen receptors (CARs), is a successful therapeutic strategy against certain hematologic malignancies. In contrast, so far it has failed against solid tumors. Given the scarcity of tumor-specific antigens, the vast majority of BiTEs and CAR Ts developed to date have been directed against tumor-associated antigens. These are expressed in some normal tissues and, as a consequence, frequent and serious side effects caused by on-target off-tumor activity have limited the use of BiTEs and CARs in the clinic. P95HER2 is a fragment of the tyrosine kinase receptor HER2 expressed in more than 30% of HER2-amplified tumors. It has been previoulsy shown that p95HER2 is a tumor-specific antigen. Here we present the generation of CARs targeting p95HER2. p95HER2 CAR T cells show remarkable activity against p95HER2-expressing cells in vitro and in vivo. Further, they are also effective against lung and brain metastasis. These tumor-specific CAR T cells could be used in the near future to deliver additional anti-tumor therapies in a safe manner.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors 95%
- Tumor-associated macrophages confer resistance to chemotherapy (Trifluridine/Tipiracil) in digestive cancers by overexpressing Thymidine Phosphorylase 94%
- Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis 93%
Similar papers in this journal
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 95%
- CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma 94%
- CD20 expression regulates CD37 levels in B-cell lymphoma: implications for immunotherapies. 94%
Similar papers in this journal
- Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition 93%
- Focused ultrasound ablation of melanoma with boiling histotripsy yields abscopal tumor control and antigen-dependent dendritic cell activation 93%
- Imaging CRISPR-Edited CAR-T Cell Therapies with Optical and Positron Emission Tomography Reporters 93%
Similar papers in this journal
- HERC1 regulates breast cancer cells migration and invasion 94%
- Blocking Gi/o-coupled signaling eradicates cancer stem cells and sensitizes breast tumors to HER2-targeted therapies to inhibit tumor relapse 94%
- PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer 93%
Similar papers in this journal
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies 95%
- CXCR6 by increasing retention of memory CD8 T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer 94%
- HERV-derived epitopes represent new targets for T-cell based immunotherapies in ovarian cancer 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.